Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Muthu Veeraputhiran

Concepts (120)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hematopoietic Stem Cell Transplantation
9
2023
580
1.940
Why?
Hematologic Neoplasms
2
2021
99
0.770
Why?
Blood Platelets
3
2011
253
0.670
Why?
Transplantation Conditioning
2
2017
88
0.640
Why?
Hematopoietic Stem Cells
2
2011
197
0.640
Why?
Comorbidity
1
2017
621
0.480
Why?
Melphalan
1
2015
177
0.450
Why?
Graft vs Host Disease
3
2023
85
0.450
Why?
Leukocytes
2
2011
69
0.440
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2014
56
0.440
Why?
Granulocyte Colony-Stimulating Factor
1
2014
63
0.440
Why?
Hematopoietic Stem Cell Mobilization
1
2014
58
0.440
Why?
Cyclophosphamide
1
2014
168
0.420
Why?
Hemagglutination Tests
1
2011
7
0.380
Why?
Aldehyde Dehydrogenase
1
2011
25
0.370
Why?
Isoantibodies
1
2011
29
0.370
Why?
Transplantation, Autologous
4
2015
480
0.360
Why?
Plateletpheresis
1
2010
7
0.350
Why?
Blood Preservation
1
2010
26
0.350
Why?
Cryopreservation
1
2010
33
0.340
Why?
Blood Proteins
1
2010
83
0.340
Why?
Anaphylaxis
1
2010
70
0.330
Why?
Graft vs Leukemia Effect
1
2009
3
0.330
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2009
45
0.320
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2015
997
0.310
Why?
Rhabdomyolysis
1
2008
12
0.300
Why?
Multiple Myeloma
2
2015
2990
0.300
Why?
Anticholesteremic Agents
1
2008
27
0.300
Why?
Simvastatin
1
2008
29
0.300
Why?
Quinazolines
1
2008
33
0.300
Why?
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
2024
11
0.290
Why?
Protein Kinase Inhibitors
1
2008
204
0.260
Why?
Immunotherapy, Adoptive
2
2024
161
0.250
Why?
Antibodies, Monoclonal
1
2009
459
0.250
Why?
Pyrazoles
2
2023
111
0.240
Why?
Aged
8
2024
9738
0.240
Why?
Humans
17
2024
50417
0.240
Why?
Neoplasm Recurrence, Local
2
2024
622
0.230
Why?
Time Factors
1
2010
2933
0.220
Why?
Acetamides
1
2023
19
0.220
Why?
Adult
8
2024
13561
0.210
Why?
Platelet Transfusion
2
2015
29
0.210
Why?
Retrospective Studies
6
2024
6274
0.210
Why?
Middle Aged
7
2024
12579
0.210
Why?
Antigens, CD34
2
2011
75
0.180
Why?
Cell Count
2
2011
150
0.180
Why?
Graft Survival
2
2011
160
0.170
Why?
Heart Rate
1
2021
304
0.170
Why?
Cell Survival
2
2011
587
0.160
Why?
Incidence
1
2021
1027
0.150
Why?
Liver Transplantation
1
2020
156
0.150
Why?
Cytomegalovirus Infections
1
2017
37
0.140
Why?
Transplantation, Homologous
1
2017
146
0.140
Why?
Appendicitis
1
2017
61
0.130
Why?
Young Adult
3
2024
4075
0.130
Why?
Regression Analysis
1
2017
376
0.130
Why?
Antineoplastic Agents, Alkylating
1
2016
73
0.130
Why?
Female
7
2024
27053
0.130
Why?
Dendritic Cells
1
2016
135
0.120
Why?
Carmustine
1
2015
14
0.120
Why?
Postoperative Hemorrhage
1
2015
52
0.120
Why?
Cytarabine
1
2015
37
0.120
Why?
Etoposide
1
2015
77
0.120
Why?
Bronchoscopy
1
2015
74
0.120
Why?
Thrombocytopenia
1
2015
82
0.120
Why?
Survival Rate
1
2017
906
0.120
Why?
Salvage Therapy
1
2015
137
0.110
Why?
Disease-Free Survival
1
2015
439
0.110
Why?
Drug Substitution
1
2014
9
0.110
Why?
Drug Evaluation
1
2014
28
0.110
Why?
Blood Cell Count
1
2014
39
0.110
Why?
Benzylamines
1
2014
15
0.110
Why?
Male
7
2024
25867
0.110
Why?
Heterocyclic Compounds
1
2014
29
0.110
Why?
Drug Synergism
1
2014
149
0.110
Why?
Risk Assessment
1
2017
1268
0.100
Why?
Nitriles
2
2023
52
0.100
Why?
Prognosis
1
2017
1974
0.100
Why?
Immune Tolerance
1
2011
83
0.090
Why?
Skin Neoplasms
1
2016
492
0.090
Why?
Pyrimidines
2
2023
187
0.090
Why?
Dimethyl Sulfoxide
1
2010
13
0.090
Why?
Isotonic Solutions
1
2010
17
0.090
Why?
P-Selectin
1
2010
31
0.090
Why?
Sodium Chloride
1
2010
56
0.090
Why?
Platelet Aggregation
1
2010
70
0.090
Why?
Platelet Activation
1
2010
46
0.080
Why?
Feasibility Studies
1
2011
389
0.080
Why?
Hypersensitivity
1
2010
76
0.080
Why?
Sensitivity and Specificity
1
2011
855
0.080
Why?
Atenolol
1
2008
13
0.070
Why?
Azetidines
1
2008
6
0.070
Why?
Amlodipine
1
2008
13
0.070
Why?
Anti-Inflammatory Agents
1
2009
165
0.070
Why?
Hyperlipidemias
1
2008
52
0.070
Why?
Drug Interactions
1
2008
207
0.070
Why?
Tumor Necrosis Factor-alpha
1
2009
386
0.070
Why?
Antihypertensive Agents
1
2008
129
0.070
Why?
Aspirin
1
2008
112
0.070
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2008
120
0.070
Why?
Carcinoma, Non-Small-Cell Lung
1
2008
153
0.060
Why?
Antigens, CD19
1
2024
28
0.060
Why?
Coronary Artery Disease
1
2008
281
0.060
Why?
Treatment Outcome
2
2024
5265
0.060
Why?
Adolescent
2
2024
6453
0.050
Why?
Hypertension
1
2008
545
0.050
Why?
Tomography, X-Ray Computed
1
2008
1163
0.050
Why?
Lung Neoplasms
1
2008
597
0.050
Why?
Chronic Disease
1
2023
573
0.050
Why?
Child
1
2011
6931
0.040
Why?
Ganciclovir
1
2017
25
0.040
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2017
82
0.030
Why?
Antiviral Agents
1
2017
171
0.030
Why?
Platelet Count
1
2015
65
0.030
Why?
Leukemia, Myeloid, Acute
1
2016
180
0.030
Why?
Bone Marrow
1
2016
360
0.030
Why?
Biopsy
1
2016
588
0.030
Why?
Practice Guidelines as Topic
1
2015
473
0.020
Why?
Antineoplastic Agents
1
2017
1165
0.020
Why?
Aged, 80 and over
1
2015
3233
0.020
Why?
Veeraputhiran's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description